Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0024141 (systemic lupus erythematosus)
 44,322 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The effect of 15-deoxyspergualin, a newly developed anti-tumor agent, on the development of spontaneously occurring lupus glomerulonephritis in male BXSB and MRL/lpr mice was examined. The prophylactic effect of 15-deoxyspergualin was evaluated using 8-week-old male BXSB mice. Its therapeutic effect was estimated using male BXSB and MRL/lpr mice of 13 weeks of age. Treatment with 15-deoxyspergualin at a dose of 5 mg/kg for 5 weeks suppressed the increment of IgG-producing cells in the spleen, decreased serum levels of circulating immune complexes assessed by solid-phase C1q-binding assay and effectively prevented the deposition of immune complexes in renal glomeruli estimated by immunofluorescent studies in both strains of mice. 15-Deoxyspergualin was also effective in preventing the massive lymphoproliferation characteristic of MRL/lpr mice as assessed by the weight of mesenteric lymph nodes. It seemed quite valuable that 15-deoxyspergualin drastically suppressed the progress of polyclonal B cell activation in both strains of autoimmune mice, which have different mechanisms leading to B cell activation. These results suggest that 15-deoxyspergualin might be used as a therapeutic agent for human erythematosus.
 ...
PMID:Immunosuppressive activities of deoxyspergualin. I. Effect of the long-term administration of the drug on the development of murine lupus. 342 22

After improvement of the prognosis of the primary systemic vasculitides and systemic lupus erythematosus from a desperate diagnosis with hardly a one year survival after diagnosis to a 5-year-survival-rate of more than 90% actual therapeutic regimes aim at those patients refractory to standard therapeutic regimes, not achieving a remission by standard approaches or having organ damage or contraindications. Furthermore less toxic regimes are looked for with the aim to avoid secondary complications of the standard therapy. New drugs used successfully in rheumatology, transplantation medicine and haematology are used for these purposes in the last years. Recent experiences with Infliximab, Mycophenolate Mofetil, Rituximab und Deoxyspergualin for the treatment of the small vessel vasculitides and systemic lupus erythematosus are reviewed.
 ...
PMID:[New therapeutic concepts for vasculitis and collagenosis]. 1626 76